Common Supplement Shows Concerning Link to Heart Failure

New research presented at the American Heart Association's Scientific Sessions indicates that long-term melatonin use (over one year) is associated with an 89% higher risk of heart failure and a doubled risk of all-cause mortality over five years, based on an analysis of over 130,000 adults. While preliminary and not yet peer-reviewed, these findings challenge the perception of melatonin as a benign long-term therapy, potentially signaling increased regulatory scrutiny or shifts in consumer demand for the widely used over-the-counter supplement, impacting manufacturers and the broader healthcare supplement market.

Analysis

New preliminary research presented at the American Heart Association's Scientific Sessions indicates significant health risks associated with long-term melatonin use. The analysis of over 130,000 adults found that individuals prescribed melatonin for more than one year faced an 89% higher risk of heart failure and a doubled risk of all-cause mortality over a five-year period. A secondary analysis further revealed a 3.5-fold increase in heart failure hospitalizations for long-term users.

These findings challenge the prevailing perception of melatonin as a benign long-term therapy, especially given its status as the fourth most popular natural product in the US, widely available over-the-counter. While the study is not yet peer-reviewed and has methodological limitations, experts are calling for further prospective trials to clarify its safety profile. This development could trigger increased regulatory scrutiny on the supplement industry and potentially impact consumer demand for melatonin products.

The moderately negative sentiment and moderate market impact score suggest that manufacturers and distributors of melatonin supplements could face headwinds. The potential for stricter regulations on dosage, labeling, or availability, similar to prescription-only status in the UK, represents a material risk. This situation underscores the need for comprehensive research into long-term supplement effects, particularly as the market for such products continues to grow.

Key Decisions for Investors

• Monitor regulatory developments closely for the dietary supplement industry, particularly regarding melatonin, as increased scrutiny could impact market access and product formulations.
• Evaluate holdings in companies manufacturing or distributing melatonin supplements for potential revenue and profitability risks, considering shifts in consumer perception and demand.
• Consider the broader implications for the over-the-counter supplement market, as this research may prompt a re-evaluation of long-term safety for other widely used, unregulated products.